|1.||Saito, Motoaki: 6 articles (08/2008 - 01/2006)|
|2.||Satoh, Keisuke: 5 articles (08/2008 - 02/2006)|
|3.||Hanada, Takuya: 4 articles (08/2008 - 01/2006)|
|4.||Kinoshita, Yukako: 4 articles (10/2007 - 02/2006)|
|5.||Satoh, Itaru: 4 articles (10/2007 - 02/2006)|
|6.||Yamada, Masashi: 4 articles (10/2007 - 02/2006)|
|7.||Suzuki, Hiroto: 4 articles (10/2007 - 02/2006)|
|8.||Kono, Tomoharu: 3 articles (09/2006 - 02/2006)|
|9.||Kazuyama, Emi: 2 articles (08/2008 - 10/2007)|
|10.||Kanzaki, Susumu: 2 articles (08/2008 - 01/2006)|
|1.||Parkinson Disease (Parkinson's Disease)
|2.||Diabetic Nephropathies (Diabetic Nephropathy)
08/01/2008 - "Our data suggest that N-hexacosanol improves diabetes-induced NOS alterations in the kidney, resulting in the amelioration of diabetic nephropathy."
08/21/2006 - "In this study we investigated the effects of N-hexacosanol on streptozotocin-induced rat diabetic nephropathy. "
08/01/2008 - "We attempted to clarify the effects of cyclohexenonic long-chain fatty alcohol (N-hexacosanol) on nitric oxide synthase (NOS) in streptozotocin-induced diabetic nephropathy. "
|4.||Body Weight (Weight, Body)
09/18/2006 - "Treatment with N-hexacosanol did not alter the diabetic status of the animals, i.e., body weight, serum glucose, and serum insulin levels, but significantly restored the thickness of intestine wall and ameliorated diabetes-induced hypercontractility of the rat ileum in a dose-dependent manner. "
01/01/2006 - "Treatment with either 2 or 8 mg/kg N-hexacosanol did not alter diabetic rat status, i.e., body weight, serum glucose or serum insulin levels, but it significantly reversed the decrease in tracheal wall thickness and diabetes-induced hypercontractility in the rat trachea. "
|5.||Nitric Oxide Synthase (NO Synthase)